retatrutide telehealth Peptide Therapy Retatrutide Availability: Everything You Need

Smoked salmon on whole-grain crispbread

Key Takeaway: Ozempic and other GLP-1 drugs reduce the calorie and nutrient intake your body relies on for muscle recovery

On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery

the antibodies are designed against those small-molecule structures

Retatrutide achieved 24% loss in 48 weeks while semaglutide achieved 17% in 68 weeks and tirzepatide achieved 22% in 72 weeks

10.1016/j.cell.2015.11.001 71